FDA approves RYTELO by Geron for myelodysplastic syndromes

FDA approves RYTELO by Geron for myelodysplastic syndromes

Geron Corporation (Nasdaq: GERN), a pioneering biopharmaceutical company focused on changing the course of blood cancer treatment, has announced a landmark achievement with the U.S. Food and Drug Administration (FDA) approval of RYTELO (imetelstat) for adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia. This approval addresses a critical need for […]